Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the
safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will
be tested in late stage, advanced illness patients who have constipation caused by opioid
pain relievers. This study will last 3 months.
Phase:
Phase 4
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.